It is possible to narrow down the field! An article introducing antibodies that distinguish phosphorylated Ser.
Antibody artisans conduct selection in vitro against fixed antigens without using animal immunity. This allows for binding reactions to be performed in the state or environment of prepared peptides or proteins, enabling precise antigen design, such as narrowing down the area of interest. Here, we present an example of antibody production using peptide antigens to obtain antibodies that recognize specifically phosphorylated proteins at certain Ser residues. We invite you to read on. [Contents] 1. Preparation of Antigens 2. Selection to Increase Specificity 3. Selection of Antibodies 4. Summary *For detailed content of the article, please refer to the related links. *For detailed specifications, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
【Details of the Content】 ■1. Preparation of Antigens ・1-1. Narrow down the target area ・1-2. Set up antigens and negative control antigens ・1-3. Synthesize peptides ■2. Selection to Increase Specificity ・2-1. Exclude antibodies that bind to ends, etc. ・2-2. Increase selection pressure with multiple antigens 2-2-1. Selection using phages (panning) 2-2-2. Selection with antibodies expressed in E. coli (ELISA) ■3. Selection of Antibodies ・3-1. Investigate the signal-to-noise ratio using ELISA ・3-2. Confirm the nucleotide sequence of the antibodies ■4. Summary *The detailed content of the article can be viewed through the related links. *For detailed specifications, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
*You can view the detailed content of the article through the related link. *For detailed specifications, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Gene Frontier has been expanding its business areas that contribute to the acceleration of biopharmaceuticals, including antibody drugs, and has been advancing the development of its unique technologies. Moving forward, we aim to accelerate our research and development and business development to achieve further growth on a global scale. We will continue to provide unique technologies and services for the development of innovative pharmaceuticals and diagnostic drugs, striving to be a trusted partner for our customers and contribute to 21st-century healthcare.
